Activating mutations of the IRS-2 have been implicated in the pathogenesis of chronic myeloid leukemia refractory to tyrosine kinase inhibitor treatment [120]. The gene discussed is IRS2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.